Elranatamab-Bcmm 40 Mg/Ml Subcutaneous Solution

Elranatamab-Bcmm 40 Mg/Ml Subcutaneous Solution
Elranatamab-Bcmm is a subcutaneous solution containing 40 mg/ml for the treatment of a specific condition.
Active Ingredient: Elranatamab-Bcmm 40 Mg/Ml Subcutaneous Solution
Minimum Market Price: 0.1

Side Effects

Tiredness, muscle/joint pain, nausea, decreased appetite, or diarrhea may occur. Pain, bruising, redness, itching, or swelling at the injection site may also occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

People using this medication may have serious side effects. However, you have been prescribed this drug because your doctor has judged that the benefit to you is greater than the risk of side effects. Careful monitoring by your doctor may decrease your risk.

Tell your doctor right away if you have any serious side effects, including: easy bruising/bleeding, signs of liver disease (such as nausea/vomiting that doesn't stop, stomach/abdominal pain, yellowing eyes/skin, dark urine), signs of anemia (such as unusual tiredness, pale skin).

This medication may lower your ability to fight infections. This may make you more likely to get a serious (rarely fatal) infection or make any infection you have worse. Tell your doctor right away if you have any signs of infection (such as sore throat that doesn't go away, fever, chills, cough).

Elranatamab can cause a rash that is usually not serious. However, you may not be able to tell it apart from a rare rash that could be a sign of a severe reaction. Tell your doctor right away if you develop any rash.

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US – Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.

In Canada – Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Uses

This medication is used to treat a certain type of cancer (multiple myeloma). Elranatamab works by slowing or stopping the growth of cancer cells.

How to use Elranatamab-Bcmm 40 Mg/Ml Subcutaneous Solution

Read the Medication Guide provided by your pharmacist before you start using elranatamab and each time you get a treatment. If you have any questions, ask your doctor or pharmacist. Carry the Patient Wallet Card with you at all times. Show the card to all of your health care providers to let them know that you are being treated with elranatamab.

This medication is given by injection under the skin as directed by your doctor. The injection is given by a health care professional, usually under the skin of the abdomen or thigh. To reduce your risk of side effects, your doctor will start this medication at a low dose and gradually increase your dose. These starting doses are part of a “step-up dosing schedule.” You must stay in the hospital for 48 hours after your first “step-up” dose and 24 hours after the second “step-up” dose so your doctor can monitor you closely and help you manage any side effects. The treatment schedule is based on your medical condition and response to treatment.

Before you receive this medication, your doctor will prescribe other medications (such as amoxilzithromaxflagyllevofloxacincipro antibiotic, dexamethasone) to help prevent side effects. Your doctor may also prescribe other medications (such as antibiotics, antivirals) to help prevent infection. Carefully follow your doctor's directions for all your medications.

Warnings

Elranatamab may cause a certain serious (even fatal) side effect known as cytokine release syndrome-CRS. Careful monitoring and prompt treatment may decrease your risk. Tell your doctor right away if you develop symptoms such as fever, chills, headache, fast heartbeat, trouble breathing, or dizziness/lightheadedness.

This medication can also cause serious (even fatal) nervous system problems. Tell your doctor right away if you have any symptoms such as confusion, trouble staying awake, changes in your handwriting, shaking, trouble speaking, or burning/throbbing/stabbing pain.

To receive this medication in the United States, you must understand, agree to, and carefully follow the requirements of the Elrexfio REMS Program. If you live in Canada or any other country, consult your doctor and pharmacist for your country's regulations.

Precautions

Before using elranatamab, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: current/recent infections.

This drug may make you dizzy or affect your thinking and coordination. Alcohol or marijuana (cannabis) can worsen these effects. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).

This medication can make you more likely to get infections or may make current infections worse. Stay away from anyone who has an infection that may easily spread (such as chickenpox, COVID-19, measles, flu). Talk to your doctor if you have been exposed to an infection or for more details.

Tell your health care professional that you are using elranatamab before having any immunizations/vaccinations. Avoid contact with people who have recently received live vaccines (such as flu vaccine inhaled through the nose).

To lower the chance of getting cut, bruised, or injured, use caution with sharp objects like razors and nail cutters, and avoid activities such as contact sports.

Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).

Tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while using elranatamab. Elranatamab may harm an unborn baby. Your doctor should order a pregnancy test before you start this medication. Ask about reliable forms of birth control while using this medication and for 4 months after the last dose. If you become pregnant, talk to your doctor right away about the risks and benefits of this medication.

It is unknown if this drug passes into breast milk. Because of the possible risk to the infant, breast-feeding while using this drug and for 4 months after the last dose is not recommended. Consult your doctor before breast-feeding.

Overdose

If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

Lab and/or medical tests (such as complete blood count, liver function) should be done before you start using this medication and while you are using it. Keep all medical and lab appointments. Consult your doctor for more details.

It is important to get each dose of this medication as scheduled. If you miss a dose, ask your doctor or pharmacist right away for a new dosing schedule.

Not applicable. This medication is given in a hospital or clinic and will not be stored at home.

Interactions

Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.

Respond: 0
Rating:
(5)
Minimum Market Price
$0.1